Skip to main content
. 2017 May 19;108(5):1007–1012. doi: 10.1111/cas.13230

Table 1.

Baseline characteristics and prior treatments (safety analysis set, N = 17)

Value
Sex, n (%) Male 13 (76.5)
Female 4 (23.5)
Age, n (%) Median (range) 63.0 (29‐83)
<65 years 9 (52.9)
≥65 years 8 (47.1)
Time since diagnosis, months Median (range) 24.0 (8.9‐89.0)
ECOG PS, n (%) 0 8 (47.1)
1 9 (52.9)
Disease subtype, n (%) Nodular sclerosis 8 (47.1)
Lymphocyte rich 0 (0.0)
Mixed cellularity 6 (35.3)
Lymphocyte depleted 2 (11.8)
Unclassified 1 (5.9)
Disease stage at study enrolment, n (%) II 4 (23.5)
III 5 (29.4)
IV 8 (47.1)
B symptoms, n (%) Absent 12 (70.6)
Present 5 (29.4)
Relapse or refractory (to most recent therapy), n (%) Relapse 1 (5.9)
Refractory 16 (94.1)
Number of prior chemotherapy regimens Median (range) 3 (2–5)
Prior brentuximab vedotin 17 (100.0)
BOR to brentuximab vedotin, n (%) CR 2 (11.8)
PR 5 (29.4)
SD 4 (23.5)
PD 5 (29.4)
Not evaluated 1 (5.9)
Prior ASCT, n (%) 5 (29.4)
BOR to ASCT, n (%) CR 3 (60.0)
PR 1 (20.0)
SD 1 (20.0)
Prior radiotherapy, n (%) 9 (52.9)

Data are presented as the n (%), unless otherwise indicated. ASCT, autologous stem cell transplantation; BOR, best overall response; CR, complete remission; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; PR, partial remission; SD, stable disease. †Relapse indicates best response of complete remission to the most recent prior therapy, and refractory indicates best response of partial remission, stable disease, or progressive disease to the most recent prior therapy.